Equashield

New York, United States Founded: 2009 • Age: 17 yrs Unicorn
Closed-system transfer devices for hazardous drug handling are developed.

About Equashield

Equashield is a Healthcare company based in New York (United States) founded in 2009 by Eric Shem Tov and Marino Kriheli. Closed-system transfer devices for hazardous drug handling are developed. Equashield has raised $300 million across 1 funding round from investors including Altshuler Shaham and Nordic Capital. The company has 142 employees. Equashield was last valued at $1.3 billion in December 2022. Its chief executive, as recorded, is Eric Shem Tov. Its Indian entity Ashield Technologies Private Limited reported revenue of ₹1.86 Cr. Its focus areas include Life Sciences, Hospital Equipment, Occupational Hazard Prevention and CSTD Devices. Its competitors include ICU Medical, Carmel Pharma and Corvida Medical; 1 of its 3 listed competitors has raised funding.

Company details

Equashield was founded in 2009 and is based in New York, United States. Operations focus on the healthcare sector, where closed-system transfer devices are developed for managing hazardous drugs. The EQUASHIELD Pro automated compounding robot is utilized to prepare individual doses, ensuring accuracy while reducing errors in medication and dosage. Exposure risks to healthcare workers from hazardous drugs and vapors are mitigated through these systems.

  • Headquarters New York, United States
  • Employees 142
  • Founders Eric Shem Tov, Marino Kriheli
  • Stage Unicorn
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website equashield.com
  • Social LinkedIn X Facebook
  • Legal Name Equashield Llc
  • Date of Incorporation 18 Jun, 2018
  • Jurisdiction Bangalore, Karnataka, India
Key Metrics
  • Indian entity revenue
    ₹1.86 Cr

    FY 2024 · +44% YoY

  • Indian entity net loss
    -₹1.24 Cr

    FY 2024 · -67% margin

  • Indian entity EBITDA
    -₹1.20 Cr

    FY 2024 · -65% margin

  • Total Equity Funding
    $300M (USD)

    in 1 rounds

  • Latest Funding Round
    $300M (USD), Series D

    Oct 2022

  • Investors
  • Employee Count
    142

Funding Insights of Equashield

Equashield has successfully raised a total of $300M through 1 strategic funding round. The most recent funding activity was a Series D round of $300 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $300M
  • Total Rounds 1
  • Last Round Series D — $300M
  • First Round $300M

    (Oct 2022)

  • Investors Count 2

All 1 funding rounds of Equashield with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2022$300MSeries D$1.3B–
Valuation history
DateValuationStage
Oct 2022$1.3B••••••••

Last known valuation $1.3B (Dec 2022). 2 investors in total: 2 institutional.

Investors in Equashield

Equashield has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Altshuler Shaham and Nordic Capital.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
nordiccapital.com
Diversified investment management services are provided to various clients.
1990as-invest.co.ilTel Aviv, Israel
Premium access

Investor details for Equashield

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Ashield Technologies Private Limited (Equashield)

Ashield Technologies Private Limited is the primary company behind Equashield. The board of Ashield Technologies Private Limited currently have 2 directors; the longest-serving is Balaga Sekhar Rao, appointed in 2018. 1 earlier director has ceased.

DirectorDesignationAppointedTenureEntity
Balaga Sekhar Rao
DIN 00364568
Director18 Jun 20188 yrs 5 moAshield Technologies Private Limited
Yashraaj Balaga
DIN 08019602
Director18 Jun 20188 yrs 5 moAshield Technologies Private Limited

People of Equashield

2 people are tracked at Equashield (2 in leadership); the tracked headcount is 142.

NameRoleGroup
Eric Shem Tov
Co-Founder & CEO & OwnerLeadership
Marino Kriheli
Co-FounderLeadership
Premium access

Complete people profiles for Equashield

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Equashield

Figures of Ashield Technologies Private Limited, the primary company behind Equashield, for FY 2024. Revenue was ₹1.86 Cr (+44% year on year). Net loss was -₹1.24 Cr (-67% margin). EBITDA was -₹1.20 Cr (-65% margin). Revenue has grown at a compounded annual rate of +35% over three years.

  • ₹1.86 CrRevenue · FY 2024 · +44% YoY
  • -₹1.24 CrNet loss · -67% margin
  • -₹1.20 CrEBITDA · -65% margin
  • ₹1 LakhPaid-up capital
  • 14Employees (provident fund records)
  • +35%Revenue CAGR, 3 years

Balance sheet, profit and loss, cash flow and ratios of Ashield Technologies Private Limited are on its company page.

Premium access

Detailed financial statements for Equashield

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Equashield

3 dated milestones of Equashield across 13 years, from founding to its latest funding, stage changes and deals.

  1. Founded Equashield is founded.
  2. Funding First funding round of $300.0M.
  3. Milestone Reaches Unicorn status.

Competitors of Equashield

Equashield has 3 listed competitors in our database, 1 of them funded. They include ICU Medical, Carmel Pharma and Corvida Medical.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
icumed.com1984San Clemente, United States6
Drug and Infusion delivery devices
carmelpharmausa.com1994Columbus, United States$2.56M
Closed-system transfer devices are produced for safe hazardous drug handling.
corvidamedical.com2008Coralville, United States5
Closed system transfer device for safe administration of hazardous drugs
Premium access

Detailed competitors of Equashield

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Equashield

The website of Equashield (equashield.com) receives about 9.8K visits a month.

  • Monthly visits
    9.8K

    ▼ 24.3% vs previous month

Similar websites

Websites whose visitors overlap most with Equashield. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
bbraunusa.com
bbraunusa.com
100%
#531,032–
drg-international.com
94%
8.7K#2,578,154View details
graylinemedical.com
87%
#238,989View details
medidose.com
medidose.com
57%
#2,631,616–
dentalwhmis.com
dentalwhmis.com
55%
–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 6 similar websites and full traffic analytics for Equashield

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Medical Equipment & Supplies

3 companies that operate in the same segment as Equashield (Medical Equipment & Supplies) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Robotic waterjet system for prostate tissue removal is developed.
2009Redwood City, California, United StatesUSD 348.84 MUSD 308.05 M756
Robotic microsurgical systems for endoscopy are developed.
2007Redwood City, California, United StatesUSD 733.62 M91
Injectable packaging, containment, and delivery solutions are manufactured.
1923Exton, Pennsylvania, United StatesUSD 8.15 B6,357
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Equashield

Frequently Asked Questions about Equashield

Equashield was founded in 2009 and raised its 1st funding round 13 years after it was founded.

Equashield is headquartered in New York, United States. It is registered at New York, New York, United States.

Eric Shem Tov is the CEO of Equashield, as recorded in our data. They have also founded this company.

Equashield is a funded company, having raised a total of $300M across 1 funding round to date. The company's 1st funding round was a Series D of $300M, raised on Oct 2022.

Equashield has 142 employees.

The primary company behind Equashield, Ashield Technologies Private Limited, reported revenue of ₹1.86 Cr for FY 2024, up 44% year on year.

Equashield was founded in 2009 and is based in New York, United States. Operations focus on the healthcare sector, where closed-system transfer devices are developed for managing hazardous drugs. The EQUASHIELD Pro automated compounding robot is utilized to prepare individual doses, ensuring accuracy while reducing errors in medication and dosage. Exposure risks to healthcare workers from hazardous drugs and vapors are mitigated through these systems.

Equashield's top competitors include ICU Medical, Carmel Pharma and Corvida Medical.

Equashield has 2 investors. Key investors include Altshuler Shaham, and Nordic Capital.

The valuation of Equashield is $1.3B as of Dec 2022.

Equashield operates through Ashield Technologies Private Limited.

The legal entities of Equashield currently have 2 directors, including Balaga Sekhar Rao, Yashraaj Balaga.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available